In clinical trials, Semaglutide resulted in an average weight loss of 15% over 68 weeks, while Tirzepatide achieved up to 20% over 72 weeks, both paired with diet and exercise
Need for Further Studies The medical community recognizes that side effects from newer medications like semaglutide need ongoing monitoring
Sin embargo, estos estudios presentan limitaciones metodolgicas significativas, incluyendo tamaos de muestra pequeos, falta de estandarizacin de dosis, alta heterogeneidad entre estudios y variabilidad en las poblaciones estudiadas
When taking oral semaglutide, it is essential to follow the fasting window closely and avoid rich foods early in the day to minimize stomach upset
However, insurer participation is voluntary